A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Healthy Subjects

Interventions

DRUG

PF-06648671

Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses

DRUG

Placebo

Placebo which will be dosed as oral suspension, single doses to match PF-06648671

Trial Locations (2)

California Clinical Trials Medical Group, Inc., Glendale

Glendale Adventist Medical Center, Glendale